1.1. Background: Inflammatory Bowel Diseases (IBD) are a set of disorders of idiopathic and multifactorial etiology, composed of two main entities: Ulcerative Colitis (UC) and Crohn's Disease (CD). The pathophysiology relies on inflammatory responses of the intestinal wall. Modern western dietary habits lack fibers and short-chain fatty acids (SCFAs), contributing to dysbiosis and malnutrition. Prebiotics are non-digestible oligosaccharides present in foods with a high amount of fiber and depend on microorganisms' action to be metabolized. This paper aimed to build a systematic review of the effects of IBD.
Methods:This review included studies available in MEDLINE-PubMed, EMBASE, and Cochrane databases, and the final selection included ten studies performed in humans. Our results show that ten studies investigated the use of prebiotics in humans. Therapies with prebiotics could improve and correct the microbiome imbalance caused by gut diseases, dietary habits, and drug administration. Thus, they could be considered as adjuvant therapy for IBD. However, the included studies were performed with a low number of patients, with different doses, different types of prebiotics, and therapy duration.
Conclusion:We suggest that more clinical trials are needed to elucidate the correct doses, types of prebiotics, and treatment duration to reach beneficial results for IBD patients.